American Journal of Kidney Diseases
Volume 53, Issue 4 , Pages 701-710 , April 2009

Acute and Chronic Management of Atrial Fibrillation in Patients With Late-Stage CKD

  • Wilbert S. Aronow, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Wilbert S. Aronow, MD, Cardiology Division, New York Medical College, Macy Pavilion, Room 138, Valhalla, NY 10595

References 

  1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988
  2. Aronow WS, Ahn C, Gutstein H. Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients. J Am Geriatr Soc. 1996;44:521–523
  3. Aronow WS, Ahn C, Gutstein H. Prevalence and incidence of cardiovascular disease in 1,160 older men and 2,464 older women in a long-term health care facility. J Gerontol A Biol Sci Med Sci. 2002;57:M45–M46
  4. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994;74:236–241
  5. Mendelson G, Aronow WS. Underutilization of warfarin in older persons with chronic nonvalvular atrial fibrillation at high risk for developing stroke. J Am Geriatr Soc. 1998;46:1423–1424
  6. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96:2455–2461
  7. Danias PG, Caulfield TA, Weigner MJ, Silverman DI, Manning WJ. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol. 1998;31:588–592
  8. Abe S, Yoshizawa M, Nakanishi N, et al. Electrocardiographic abnormalities in patients receiving hemodialysis. Am Heart J. 1996;131:1137–1144
  9. Fabbian F, Catalano C, Lambertini D, et al. Clinical characteristics associated to atrial fibrillation in chronic hemodialysis patients. Clin Nephrol. 2000;54:234–239
  10. Vazquez E, Sanchez-Perales C, Borrego F, et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J. 2000;140:886–890
  11. Genovesi S, Pogliani D, Faini A, et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis. 2005;46:897–902
  12. Das M, Aronow WS, McClung JA, Belkin RN. Increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium in patients with chronic renal insufficiency. Cardiol Rev. 2006;14:14–17
  13. Atar I, Konas D, Acikel S, et al. Frequency of atrial fibrillation and factors related to its development in dialysis patients. Int J Cardiol. 2006;106:47–51
  14. Abbott KC, Trespalacios FC, Taylor AJ, Agodoa LY. Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality. BMC Nephrol. 2003;4:1
  15. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: The Framingham Study. N Engl J Med. 1982;306:1018–1022
  16. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death (The Framingham Heart Study). Circulation. 1998;98:946–952
  17. Aronow WS, Ahn C, Mercando AD, Epstein S. Correlation of atrial fibrillation, paroxysmal supraventricular tachycardia, and sinus rhythm with incidences of new coronary events in 1,359 patients, mean age 81 years, with heart disease. Am J Cardiol. 1995;75:182–184
  18. Friberg J, Scharling H, Gadsboll N, et al. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (the Copenhagen City Heart Study). Am J Cardiol. 2004;94:889–894
  19. Dagres N, Nieuwlaat R, Vardas PE, et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe (A report from the Euro Heart Survey on Atrial Fibrillation). J Am Coll Cardiol. 2007;49:572–577
  20. Aronow WS, Ahn C, Mercando AD, Epstein S, Gutstein H. Correlation of paroxysmal supraventricular tachycardia, atrial fibrillation, and sinus rhythm with incidences of new thromboembolic stroke in 1,476 old-old patients. Aging Clin Exp Res. 1996;8:32–34
  21. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke (Results from the national registry of atrial fibrillation). JAMA. 2001;285:2864–2870
  22. Khumri TM, Idupulapati M, Rader VJ, Nayyar S, Stoner CN, Main ML. Clinical and echocardiographic markers of mortality risk in patients with atrial fibrillation. Am J Cardiol. 2007;99:1733–1736
  23. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339:799–805
  24. D'Elia JA, Weinrauch LA, Gleason RE, et al. Application of the ambulatory 24-hour electrocardiogram in the prediction of cardiac death in dialysis patients. Arch Intern Med. 1988;148:2381–2385
  25. Jungers P, Massy ZA, Khoa TN, et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant. 1997;12:2597–2602
  26. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol. 1999;10:1608–1615
  27. Aronow WS, Ahn C, Mercando AD, Epstein S. Prevalence of coronary artery disease, complex ventricular arrhythmias, and silent myocardial ischemia and incidence of new coronary events in older persons with chronic renal insufficiency and with normal renal function. Am J Cardiol. 2000;86:1142–1143
  28. Genovesi S, Vincenti A, Rossi E, et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis. 2008;51:255–262
  29. Vazquez E, Sanchez-Perales C, Lozano C, et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol. 2003;92:868–871
  30. Vazquez-Ruiz de Castroviejoa E, Sanchez-Perales C, Lozano-Cabezas C, et al. Incidence of atrial fibrillation in hemodialysis patients (A prospective long-term follow-up study). Rev Esp Cardiol. 2006;59:779–784
  31. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505–1511
  32. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation (Analysis of pooled data from five randomized controlled trials). Arch Intern Med. 1994;154:1449–1457
  33. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633–638
  34. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255–1262
  35. Peterson P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet. 1989;1:175–179
  36. Stroke Prevention in Atrial Fibrillation Investigators. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med. 1990;322:863–868
  37. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: Final results. Circulation. 1991;84:527–539
  38. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:345–355
  39. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406–1412
  40. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687–691
  41. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation (Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study). Arch Intern Med. 1998;158:1513–1521
  42. Aronow WS, Ahn C, Kronzon I, Gutstein H. Incidence of new thromboembolic stroke in persons ≥62 years old with chronic atrial fibrillation treated with warfarin versus aspirin. J Am Geriatr Soc. 1999;47:366–368
  43. Aronow WS, Ahn C, Kronzon I, Gutstein H. Effect of warfarin versus aspirin on the incidence of new thromboembolic stroke in older persons with chronic atrial fibrillation and abnormal and normal left ventricular ejection fraction. Am J Cardiol. 2000;85:1033–1035
  44. Fang MC, Singer DE, Chang Y, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation (The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study). Circulation. 2005;112:1687–1691
  45. Ruiz-Nodar JM, Marin F, Hurtado JA, et al. Anticoagulant therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation. J Am Coll Cardiol. 2008;51:818–825
  46. Korantzopoulos P, Kokkoris S, Liu T, Protopsaltis I, Li G, Goudevenos JA. Atrial fibrillation in end-stage renal disease. Pacing Clin Electrophysiol. 2007;30:1391–1397
  47. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary. Am Coll Cardiol. 2001;38:1231–1265
  48. Vazquez E, Sanchez-Perales C, Garcia-Cortes J, et al. Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants?. Int J Cardiol. 2003;87:135–139
  49. Wright JR, Kalra PA. Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants?. Int J Cardiol. 2003;87:139–141
  50. Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: A systematic review of bleeding rates. Am J Kidney Dis. 2007;50:433–440
  51. Tveit DP, Hypolite IO, Hshieh P, et al. Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis. 2002;39:1011–1017
  52. Nishimura M, Hashimoto T, Kobayashi H, et al. The high incidence of left atrial appendage thrombosis in patients on maintenance haemodialysis. Nephrol Dial Transplant. 2003;18:2339–2347
  53. Quinn RR, Naimark DMJ, Oliver MJ, et al. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? (A cost-utility analysis). Am J Kidney Dis. 2007;50:421–432
  54. Abbott KC, Neff RT, Bohen EM, Narayan R. Anticoagulation for chronic atrial fibrillation in hemodialysis patients: which fruit from the decision tree?. Am J Kidney Dis. 2007;50:345–348
  55. Aronow WS, Sorbera C. Supraventricular tachyarrhythmias in the elderly. In:  Aronow WS,  Fleg JL,  Rich MW editor. Cardiovascular Disease in the Elderly. (ed 4). New York, NY: Informa Healthcare; 2008;p. 577–603
  56. Aronow WS. Might losartan reduce sudden cardiac death in diabetics with hypertension?. Lancet. 2003;362:591–592
  57. K/DOQI Workgroup. Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis. 2005;45(suppl 3):S1–S153
  58. Frishman WH, Aronow WS, Cheng-Lai A. Cardiovascular drug therapy in the elderly. In:  Aronow WS,  Fleg JL,  Rich MW editor. Cardiovascular Disease in the Elderly. (ed 4). New York, NY: Informa Healthcare; 2008;p. 99–135
  59. Agarwal R. Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int. 1999;55:1528–1535
  60. Letavernier E, Couzi L, Delmas Y, et al. Verapamil and mild hyperkalemia in hemodialysis patients: a potentially hazardous association. Hemodial Int. 2006;10:170–172
  61. Falk RH, Leavitt JI. Digoxin for atrial fibrillation: a drug whose time has gone?. Ann Intern Med. 1991;114:573–575
  62. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:385–392
  63. Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation. 1991;83:52–60
  64. Gold RL, Haffajee CI, Charos G, et al. Amiodarone for refractory atrial fibrillation. Am J Cardiol. 1986;57:124–127
  65. Greene HL CASCADE Investigators. The CASCADE study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. Am J Cardiol. 1993;72:70F–74F
  66. Herre J, Sauve M, Malone P, Griffin JC, Helmy I, Langberg JJ. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol. 1989;13:442–449
  67. Freudenberger RS, Wilson AC, Kostis JB AFFIRM Investigators and Committees. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM study). Am J Cardiol. 2007;100:247–252
  68. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–1840
  69. Rienstra M, Van Veldhuisen DJ, Hagens VE, et al. Gender-related differences in rhythm control treatment in persistent atrial fibrillation (Data of the Rate Control Versus Electrical Cardioversion (RACE) Study). J Am Coll Cardiol. 2005;46:1298–1306
  70. Al-Khatib SM, Shaw LK, Lee KL, et al. Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure?. Am J Cardiol. 2004;94:797–800
  71. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667–2677
  72. The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–1833
  73. Hunt SA, Abraham WT, Feldman AM, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article. J Am Coll Cardiol. 2005;46:1116–1143
  74. Aronow WS. Treatment of heart failure with abnormal left ventricular systolic function in the elderly. Heart Fail Clin. 2008;3:423–436
  75. Ozcan C, Jahangir A, Friedman PA, et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med. 2001;344:1043–1051
  76. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1–S246
  77. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  78. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–559
  79. Sukhija R, Burac Z, Kakar P, et al. Effect of statins on the development of renal dysfunction. Am J Cardiol. 2008;101:975–979
  80. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Eng J Med. 2005;353:238–248

PII: S0272-6386(09)00425-9

doi: 10.1053/j.ajkd.2009.01.257

American Journal of Kidney Diseases
Volume 53, Issue 4 , Pages 701-710 , April 2009

Article Tools